Boehringer hits China’s Qilu with cancer drug patent suit

Chinese drug maker Qilu’s proposed generic version of a cancer treatment infringes three patents, according to a lawsuit filed by Boehringer Ingelheim.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Partial win for Mylan as Fed Circuit cancels Boehringer patents

17 March 2020 The US Court of Appeals for the Federal Circuit has rescued one Boehringer Ingelheim patent, covering a type 2 diabetes treatment, from invalidation but affirmed a New Jersey district court’s cancellation of two others.

Big Pharma

China unveils new drug patenting rules

11 February 2021 China has introduced new measures to enforce a patent linkage system and proposed draft rules on how a patent owner can challenge the approval of a drug.

Asia-Pacific

Australian court rejects Boehringer opposition bid against MSD unit’s anti-parasitic drug patent

24 May 2022 The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.

More on this story

Big Pharma

Partial win for Mylan as Fed Circuit cancels Boehringer patents

Big Pharma

China unveils new drug patenting rules

11 February 2021 China has introduced new measures to enforce a patent linkage system and proposed draft rules on how a patent owner can challenge the approval of a drug.

Asia-Pacific

Australian court rejects Boehringer opposition bid against MSD unit’s anti-parasitic drug patent

24 May 2022 The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.

More on this story

Big Pharma

Partial win for Mylan as Fed Circuit cancels Boehringer patents

Big Pharma

China unveils new drug patenting rules

11 February 2021 China has introduced new measures to enforce a patent linkage system and proposed draft rules on how a patent owner can challenge the approval of a drug.

Asia-Pacific

Australian court rejects Boehringer opposition bid against MSD unit’s anti-parasitic drug patent

24 May 2022 The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.

More features

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Bristol Myers Squibb leader named INTA 2025 president

Kathi Vidal to leave USPTO ahead of incoming Trump administration

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

Boehringer hits China’s Qilu with cancer drug patent suit

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features